# US 2005/0032831 A1 · Histone deacetylase inhibitors and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032831 A1
- Document ID: US20050032831A1
- Status: Published application
- Kind: A1
- Application number: 10/843,229
- Filed: 2004-05-11
- Published: 2005-02-10
- Earliest claimed: 2003-07-07
- Assignees: Georgetown University
- Inventors: Alan Kozikowski; Bin Chen
- Web page: https://patentgrep.com/patent/US20050032831A1

## CPC

- C07C 271/02: Carbamic acids; Salts of carbamic acids (unsubstituted carbamic acid or salts thereof C01B21/12)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 275/24: containing six-membered aromatic rings
- C07C 275/26: having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C 275/40: being further substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 323/44: X or Y being nitrogen atoms
- C07C 323/60: with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
- C07D 215/48: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 215/54: attached in position 3
- C07C 2603/74: Adamantanes
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

## Claims

### Claim 1

A compound having the formula
or a pharmaceutically acceptable salt thereof,
wherein:
X represents independently for each occurrence O or S;
Z represents a bond; or unsubstituted or substituted phenyl, naphthalenyl, pyridinyl, quinolinyl or isoquinolinyl, wherein a substituent on Z, if present, is selected from the group consisting of -halo, —C1-C6 alkyl, —O—(C1-C6 alkyl), —OH, —NO2, —OR′, —CN, —COOR′, —OC(O)R′, —NHR′, —N(R′)2, —NHC(O)R′ and —C(O)NHR′;
R9 is phenyl, naphthalenyl, pyridinyl, quinolinyl or isoquinolinyl; wherein R9 is unsubstituted or substituted with one or more of the following groups: phenyl, -halo, —C1-C6 alkyl, —O—(C1-C6 alkyl), —OH, —NO2, —OR′, —CN, —COOR′, —OC(O)R′, —NHR′, —N(R′)2, —NHC(O)R′ or —C(O)NHR′;
R′ is independently H or unsubstituted —C1-C6 alkyl;
m is an integer ranging from 0-5; and
n is an integer ranging from 0-5.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X represents O.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Z represents a bond.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Z represents phenyl or pyridinyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Z represents phenyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the sum of m and n is 3, 4, 5, or 6.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R9 is phenyl, 4-(dimethylamino)phenyl, 4-(phenyl)phenyl, 3-quinolinyl or 8-quinolinyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein X represents O; Z represents a bond; and the sum of m and n is 3, 4, 5, or 6.

### Claim 9 (depends on 1)

The compound of claim 1, wherein X represents O; Z represents a bond; and R9 is phenyl, 4-(dimethylamino)phenyl, 4-(phenyl)phenyl, 3-quinolinyl or 8-quinolinyl.

### Claim 10 (depends on 1)

The compound of claim 1, wherein X represents O; Z represents a bond; R9 is phenyl, 4-(dimethylamino)phenyl, 4-(phenyl)phenyl, 3-quinolinyl or 8-quinolinyl; and the sum of m and n is 3, 4, 5, or 6.

### Claim 11 (depends on 1)

The compound of claim 1, wherein X represents O; Z represents phenyl or pyridinyl; m is 1; and n is 1.

### Claim 12 (depends on 1)

The compound of claim 1, wherein X represents O; Z represents phenyl; m is 1; and n is 1.

### Claim 13 (depends on 1)

The compound of claim 1, wherein X represents O; Z represents phenyl or pyridinyl; m is 1; n is 1; and R9 is phenyl, 4-(dimethylamino)phenyl, 4-(phenyl)phenyl, 3-quinolinyl or 8-quinolinyl.

### Claim 14 (depends on 1)

The compound of claim 1, wherein X represents O; Z represents phenyl; m is 1; n is 1; and R9 is phenyl, 4-(dimethylamino)phenyl, 4-(phenyl)phenyl, 3-quinolinyl or 8-quinolinyl.

### Claim 15

A compound having the formula
or a pharmaceutically acceptable salt thereof,
wherein:
X represents independently for each occurrence O or S;
Z represents a bond; or unsubstituted or substituted phenyl, naphthalenyl, pyridinyl, quinolinyl or isoquinolinyl, wherein a substituent on Z, if present, is selected from the group consisting of -halo, —C1-C6 alkyl, —O—(C1-C6 alkyl), —OH, —NO2, —OR′, —CN, —COOR′, —OC(O)R′, —NHR′, —N(R′)2, —NHC(O)R′ and —C(O)NHR′;
R9 is phenyl, naphthalenyl, pyridinyl, quinolinyl or isoquinolinyl; wherein R9 is unsubstituted or substituted with one or more of the following groups: phenyl, -halo, —C1-C6 alkyl, —O—(C1-C6 alkyl), —OH, —NO2, —OR′, —CN, —COOR′, —OC(O)R′, —NHR′, —N(R′)2, —NHC(O)R′ or —C(O)NHR′;
R′ is independently H or unsubstituted —C1-C6 alkyl;
m is an integer ranging from 0-5; and
n is an integer ranging from 0-5.

### Claim 16 (depends on 15)

The compound of claim 15, wherein X represents O.

### Claim 17 (depends on 15)

The compound of claim 15, wherein Z represents a bond.

### Claim 18 (depends on 15)

The compound of claim 15, wherein Z represents phenyl or pyridinyl.

### Claim 19 (depends on 15)

The compound of claim 15, wherein Z represents phenyl.

### Claim 20 (depends on 15)

The compound of claim 15, wherein the sum of m and n is 3, 4, 5, or 6.

### Claim 21 (depends on 15)

The compound of claim 15, wherein R9 is phenyl, 4-(dimethylamino)phenyl, 3-quinolinyl, 6-quinolinyl, or 8-quinolinyl.

### Claim 22 (depends on 15)

The compound of claim 15, wherein X represents O; Z represents a bond; and the sum of m and n is 3, 4, 5, or 6.

### Claim 23 (depends on 15)

The compound of claim 15, wherein X represents O; Z represents a bond; and R9 is phenyl, 4-(dimethylamino)phenyl, 3-quinolinyl, 6-quinolinyl or 8-quinolinyl.

### Claim 24 (depends on 15)

The compound of claim 15, wherein X represents O; Z represents a bond; R9 is phenyl, 4-(dimethylamino)phenyl, 3-quinolinyl, 6-quinolinyl or 8-quinolinyl; and the sum of m and n is 3, 4, 5, or 6.

### Claim 25 (depends on 15)

The compound of claim 15, wherein X represents O; Z represents phenyl or pyridinyl; m is 1; and n is 1.

### Claim 26 (depends on 15)

The compound of claim 15, wherein X represents O; Z represents phenyl; m is 1; and n is 1.

### Claim 27 (depends on 15)

The compound of claim 15, wherein X represents O; Z represents phenyl or pyridinyl; m is 1; n is 1; and R9 is phenyl, 4-(dimethylamino)phenyl, 3-quinolinyl, 6-quinolinyl or 8-quinolinyl.

### Claim 28 (depends on 15)

The compound of claim 15, wherein X represents O; Z represents phenyl; m is 1; n is 1; and R9 is phenyl, 4-(dimethylamino)phenyl, 3-quinolinyl, 6-quinolinyl or 8-quinolinyl.

### Claim 29 (depends on 1, 15)

A pharmaceutical composition, comprising a compound of claim 1 or 15; and a pharmaceutically acceptable excipient.

### Claim 30 (depends on 1, 15)

A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, comprising contacting said cell with an effective amount of a compound of claim 1 or 15.

### Claim 31 (depends on 30)

The method of claim 30, wherein the cell is an in vivo cell.

### Claim 32 (depends on 1, 15)

A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 15.

### Claim 33 (depends on 32)

The method of claim 32, wherein said subject is a human.

### Claim 34 (depends on 1, 15)

A method of treating Non-Hodgkin's lymphoma, Hodgkin's disease, Ewing's sarcoma, testicular cancer, prostate cancer, larynx cancer, cervical cancer, nasopharynx cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancer, esophogeal cancer, rectal cancer, small-cell lung cancer, non-small cell lung cancer, brain cancer, or a CNS neoplasm, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 15.

### Claim 35 (depends on 34)

The method of claim 34, wherein said subject is a human.

### Claim 36 (depends on 32)

The method of claim 32, further comprising administering to said subject a therapuetically effective amount of radiotherapy.

### Claim 37 (depends on 36)

The method of claim 36, wherein said subject is a human.

### Claim 38 (depends on 34)

The method of claim 34, further comprising administering to said subject a therapuetically effective amount of radiotherapy.

### Claim 39 (depends on 38)

The method of claim 38, wherein said subject is a human.

### Claim 40 (depends on 1, 15)

A method for treating a neurological disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 15.

### Claim 41 (depends on 40)

The method of claim 40, wherein said subject is a human.

### Claim 42 (depends on 1, 15)

A method for treating Huntington's disease, lupus, or schizophrenia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or 15.

### Claim 43 (depends on 42)

The method of claim 42, wherein said subject is a human.
